Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting

Core Insights - Annexon, Inc. is advancing a late-stage clinical platform for novel therapies targeting classical complement-mediated neuroinflammatory diseases, with a focus on Guillain-Barré Syndrome (GBS) [1][4] - The company is presenting Phase 3 data for ANX005, a monoclonal antibody designed to block C1q, at the AAN Annual Meeting, highlighting its potential to improve recovery in GBS patients [1][3] Company Overview - Annexon is developing therapeutics aimed at stopping classical complement-driven neurodegeneration, targeting conditions affecting over 8 million people globally [4] - The company's approach focuses on C1q, which initiates the classical complement pathway, leading to tissue damage when misdirected [4] Industry Context - GBS is a rare autoimmune disease affecting at least 150,000 people annually worldwide, characterized by severe weakness and potential paralysis, with no FDA-approved therapies currently available [2] - The company is launching a new educational campaign, "Move GBS Forward," to raise awareness about the impact of GBS and promote timely diagnosis and care [5]